Advertisement

Topics

Endospan Company Profile

05:20 EDT 15th August 2018 | BioPortfolio

Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. Endospan has initiated the CE-marking regulatory process to market in Europe the NEXUS™ Stent Graft System, the first endovascular off-the-shelf system to treat Aortic Arch Disease: a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.


News Articles [4 Associated News Articles listed on BioPortfolio]

Endospan Appoints Kevin J. Mayberry as CEO

Former Endologix exec spearheading CE mark registration of NEXUS™ Stent Graft System for Aortic Arch Disease With its innovative NEXUS™ Stent Graft System, Endospan h...

Endospan Receives CE Mark for HORIZON™ EVAR System Based on Robust Clinical and Pivotal Data to Treat Abdominal Aortic Aneurysm (AAA)

Endospan, a pioneer in off-the-shelf EndoVascular Aortic Repair (EVAR), announced today that it has received CE marking for its HORIZON Stent Graft System to treat Abdomina...

Endospan Elects Jeff Elkins as a Director

President and CEO of Veniti, Elkins is expected to help Endospan fortify global market development of its NEXUS™ Stent Graft System for Aortic Arch Disease Endospan, ...

Israeli endovascular startup names former Endologix exec as CEO

Kevin Mayberry was appointed CEO at Endospan, an Israeli startup that develops endovascular repair technologies for aortic ar -More- 

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

The Single Branch NEXUS™ Clinical Study

A prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Subjects will be followed-up for five years.

HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm

Clinical Investigation Design A prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Patients will be followed-up for five years. Investigati...

Companies [1 Associated Companies listed on BioPortfolio]

Endospan

Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. End...

More Information about "Endospan" on BioPortfolio

We have published hundreds of Endospan news stories on BioPortfolio along with dozens of Endospan Clinical Trials and PubMed Articles about Endospan for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endospan Companies in our database. You can also find out about relevant Endospan Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...


Corporate Database Quicklinks



Searches Linking to this Company Record